Actavia Life Sciences, Inc.

RASP

US7538881068

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 19:18:48 21/06/2024 BST			5-day change	1st Jan Change
0.0016 ^USD	-82.22%		-82.22%	-79.22%

05-20	Actavia Life Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	CI
02-16	Actavia Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	CI

Kunwar Shailubhai Resigns as Chief Executive Officer of Rasna Therapeutics, Inc

February 06, 2020 at 07:37 pm

On January 31, 2020, Dr. Kunwar Shailubhai resigned as Chief Executive Officer of Rasna Therapeutics, Inc. for personal reasons.

Latest news about Actavia Life Sciences, Inc.

Actavia Life Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	05-20	CI
Actavia Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	02-16	CI
Actavia Life Sciences, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	01-05	CI
Rasna Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	14/08/23	CI
Rasna Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	15/05/23	CI
Rasna Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	02/03/23	CI
Rasna Therapeutics, Inc. Reports Earnings Results for the Full Year Ended September 30, 2022	09/02/23	CI
Rasna Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	08/02/23	CI
Rasna Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022	22/08/22	CI
Rasna Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2022	21/06/22	CI
Rasna Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2021	16/06/22	CI
Rasna Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	09/06/22	CI
Rasna Therapeutics, Inc. Reports Earnings Results for the Full Year Ended September 30, 2021	01/03/22	CI
Rasna Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended June 30, 2021	16/08/21	CI
Rasna Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended March 31, 2021	02/06/21	CI
Rasna Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2020	05/04/21	CI
Rasna Therapeutics, Inc. Reports Earnings Results for the Full Year Ended September 30, 2020	15/01/21	CI
Rasna Therapeutics, Inc. Announces Board Changes	28/12/20	CI
Rasna Therapeutics, Inc Announces Board Changes	15/10/20	CI
Rasna Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended June 30, 2020	19/08/20	CI
Rasna Therapeutics, Inc. Announces Executive Changes	18/08/20	CI
Rasna Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended March 31, 2020	30/06/20	CI
Rasna Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2019	14/02/20	CI
Kunwar Shailubhai Resigns as Chief Executive Officer of Rasna Therapeutics, Inc	06/02/20	CI
Rasna Therapeutics, Inc. Reports Earnings Results for the Full Year Ended September 30, 2019	13/01/20	CI

Chart Actavia Life Sciences, Inc.

Duration

Period

More charts

Actavia Life Sciences, Inc. is a leukemia-focused biotechnology company. The Company is engaged in developing therapeutics to address the unmet need that exists for acute myeloid leukemia (AML), and other forms of leukemia and lymphoma. AML is generally a disease of older adults. It develops small molecule drug candidates targeting the LSD1 gene, which controls pathways underlying the etiology of AML subtypes. Its RASP-201 is a novel, orally dosed, selective reversible inhibitor of lysine specific demethylase (LSD1), a pathway that blocks differentiation and confers a poor prognosis to AML. RASP-201 when dosed orally shows in vivo therapeutic utility in murine (mouse) models of AML. Its primary indication is AML which may be fatal within weeks to months.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ACTAVIA LIFE SCIENCES, INC.	-79.22%	1.23M
VERTEX PHARMACEUTICALS INCORPORATED	+15.19%	121B
REGENERON PHARMACEUTICALS, INC.	+19.91%	114B
ARGENX SE	+19.13%	23.61B
BIONTECH SE	-19.80%	20.43B
GENMAB A/S	-15.80%	16.55B
BEIGENE, LTD.	-13.45%	16.45B
WUXI APPTEC CO., LTD.	-44.35%	15.59B
SAREPTA THERAPEUTICS, INC.	+66.67%	15.19B
NEUROCRINE BIOSCIENCES, INC.	+2.13%	13.54B